REVIEW PAPER
Effect of diet on lipid profile in HIV-infected patients
 
More details
Hide details
 
Submission date: 2018-02-15
 
 
Final revision date: 2018-04-12
 
 
Acceptance date: 2018-04-30
 
 
Publication date: 2018-09-24
 
 
HIV & AIDS Review 2018;17(3):159-163
 
KEYWORDS
TOPICS
ABSTRACT
The implementation of highly active antiretroviral therapy has increased the life expectancy of people living with human immunodeficiency virus (HIV), thus reducing the number of deaths from acquired immune deficiency syndrome. Nowadays life expectancy of HIV(+) patients is comparable to those who are not infected. However, due to the use of antiretroviral therapy and the persistent immune activation and inflammation caused by HIV, other negative events may occur including dyslipidaemias, cardiovascular disorders, chronic kidney disease, early ageing, and neurocognitive impairment. It also increases the risk of developing metabolic syndrome and becomes a risk factor for cardiovascular disease: e.g. hypertension, brain stroke, and heart infarct. Comprehensive care of HIV patients with disturbed lipid profile includes lifestyle modifications such as dietary changes along with smoking cessation and has a beneficial effect on the lipid profile (total cholesterol, LDL, HDL, triglyceride levels). Therefore, it can reduce the risk of cardiovascular disease, allows the patients to avoid additional pharmacotherapy, and can eliminate drug-drug interactions with antiretroviral drugs.
There are a lot of data showing that early dietary intervention and consistent diet control have a beneficial effect on lipid disorders in HIV-infected patients. Clinicians should be aware of it. In view of the benefits that can be gained by people living with HIV from dietary intervention, it is appropriate to include dieticians in a panel of specialists who take care of HIV(+) patients.
REFERENCES (36)
1.
Montaner J, Lima V, Harrigan R, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: The “HIV Treatment as Prevention” experience in a Canadian setting. PLoS One 2014; 9: e87872.
 
2.
Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013; 39: 633-645.
 
3.
Corkery S, Hughson G. Side-effects. 2013. Available at: http://www.aidsmap.com/Side-ef... (Accessed: October 2017).
 
4.
Palios J, Kadoglou NP, Lampropoulos S. The pathophysiology of HIV-/HAART-related metabolic syndrome leading to cardiovascular disorders: the emerging role of adipokines. Exp Diabetes Res 2012; 2012: 103063.
 
5.
Jankowska M, Lemańska M, Dręczewski M. Interakcje lekowe. In: Zasady opieki nad osobami zakażonymi HIV. Zalecenia PTN AIDS. Horban A, Podlasin R, Cholewińska G et al. Polskie Towarzystwo Naukowe AIDS, Warszawa-Wrocław 2017; 92-107.
 
6.
Alcorn K, Corkery S, Hughson G. Anti-HIV drugs. 2014. Available at: http://www.aidsmap.com/Anti-HI....
 
7.
Graham I, Atar D, Borch-Johnsen K, et al. Europejskie wytyczne dotyczące prewencji chorób sercowo-naczyniowych w praktyce klinicznej – wersja skrócona. Kardiol Pol 2008; 66 (Suppl 4): 1-48.
 
8.
Sereti I, Altfeld M. Immune activation and HIV: An enduring relationship. Curr Opin HIV AIDS 2016; 11: 129-130.
 
9.
Kwiatkowska W, Bogdański P, Pulik P, et al. Postępowanie profilaktyczne, diagnostyczne i lecznicze w chorobach układu sercowo-naczyniowego u osób zakażonych HIV. In: Zasady opieki nad osobami zakażonymi HIV. Zalecenia PTN AIDS. Horban A, Podlasin R, Cholewińska G, et al. Polskie Towarzystwo Naukowe AIDS, Warszawa-Wrocław 2017; 386-394.
 
10.
Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infec Dis 2003; 37: 613-627.
 
11.
Bergersen BM. Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy. Drugs 2006; 66: 1971-1987.
 
12.
Souza SJ, Luzia LA, Santos SS, et al. Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review. Rev Assoc Med Bras (1992) 2013; 59: 186-198.
 
13.
Pająk A, Wiercińska E, Polakowska M, et al. Rozpowszechnienie dyslipidemii u mężczyzn i kobiet w wieku 20–74 lat w Polsce. Wyniki programu WOBASZ. Kardiol Pol 2005; 63 (supl. 4).
 
14.
Menzaghi B, Ricci E, Vichi F, et al. Gender differences in HIV infection: Is there a problem? Analysis from the SCOLTA cohorts. Biomed Pharmacother 2014; 68: 385-390.
 
15.
Wożakowska-Kapłon B, Barylski M, Slawa P, et al. Zalecenia postępowania w dyslipidemii – propozycje algorytmu dla lekarzy rodzinnych. 2012. Available at: http://czasopisma.viamedica.pl... (Accessed: 2 May 2014).
 
16.
Knudsen A, Kristoffersen US, Kjaer A, et al. Cardiovascular Risk in Patients with HIV Infection. Future Virology 2012; 7: 413-423.
 
17.
Lazzaretti RK, Kuhmmer R, Sprinz E, et al. Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected individuals. J Am Coll Cardiol 2012; 59: 979-988.
 
18.
Feeney ER, Mallon PW. HIV and HAART-Associated Dyslipidemia. Open Cardiovasc Med J 2011; 5: 49-63.
 
19.
International Diabetes Federation (2017). The IDF consensus worldwide definition of the metabolic syndrome. Available at: https://www.idf.org/e-library/....
 
20.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-1421.
 
21.
Cybulska B, Szostak W, Podolec P. Konsensus Rady Redakcyjnej PFP dotyczący dyslipidemii. Available at: http://www.pfp.edu.pl/download....
 
22.
Mondy K, Overton ET, Grubb J, et al. Metabolic Syndrome in HIV-Infected Patients from an Urban, Midwestern US Outpatient Population. Clin Infect Dis 2007; 44: 726-734.
 
23.
Pao V, Lee GA, Grunfeld C. HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep 2008; 10: 61-70.
 
24.
Stradling C, Chen Y, Russell T. Omega-3 Fatty Acids and Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy: Systematic Review and Meta-analysis. 2012. Available at: http://aidsinfo.nih.gov/guidel....
 
25.
Mannu GS, Zaman MJ, Gupta A, et al. Evidence of lifestyle modification in the management of hypercholesterolemia. Curr Cardiol Rev 2013; 9: 2-14.
 
26.
Jones SP, Doran DA, Leatt PB, et al. Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy. AIDS 2001; 15: 2049-2051.
 
27.
Thusqaard M, Christensen JH, Morn B, et al. Effect of fish oil (n-3 polyunsaturated fatty acids) on plasma lipids, lipoprotein and inflammatory markers in HIV-infected patients treated with antiretroviral therapy: A randomized, double-blind, placebo-controlled study. Scand J Infect Dis 2004; 41: 760-766.
 
28.
Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997; 65 (5 Suppl): 1645S-1654S.
 
29.
Mojska H, Kłosiewicz-Latoszek L, Jasińska-Melon E, et al. Kwasy tłuszczowe omega-3. In: Normy żywienia dla populacji polskiej. Jarosz M (ed.). Instytut Żywności i Żywienia, Warszawa 2017; 76-87.
 
30.
Myerson M, Poltavskiy E, Armstrong EJ, et al. Prevalence, treatment and control of dyslipidemia and hypertension in 4278 HIV outpatients. J Acquir Immune Defic Syndr 2014; 66: 370-377.
 
31.
Peters BS, Wierzbicki AS, Moyle G, et al. The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART. Clin Ther 2012; 34: 67-76.
 
32.
Gerber JG, Kitch DW, Fichtenbaum CJ, et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 2008; 47: 459-466.
 
33.
Vieira AD, Silveira GR. Effectiveness of n-3 fatty acids in the treatment of hypertriglyceridemia in HIV/AIDS patients: a meta-analysis. Cien Saude Colet 2017; 22: 2659-2669.
 
34.
Cichocka A. Dieta śródziemnomorska w profilaktyce pierwotnej choroby niedokrwiennej serca. Endokrynologia, Otyłość i Zaburzenia Przemiany Materii 2005; 1: 30-36.
 
35.
Hernáez Á, Castañer O, Goday A, et al. The Mediterranean Diet decreases LDL atherogenicity in high cardiovascular risk individuals: a randomized controlled trial. Mol Nutr Food Res 2017; 61; doi: 10.1002/mnfr.201601015.
 
36.
Turcinov D, Stanley C, Canchola J, et al. Dyslipidemia and adherence to the Mediterranean diet in Croatian HIV-infected patients during the first year of highly active antiretroviral therapy. Coll Antropol 2009; 33: 423-430.
 
eISSN:1732-2707
ISSN:1730-1270
Journals System - logo
Scroll to top